Actively Recruiting

Phase Not Applicable
Age: 21Years +
All Genders
ID06839898

A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses to Compare Outcomes in Patients With Moderate to High Myopia and Astigmatism

Led by Biotech Healthcare Holding Gmbh · Updated on 2025-02-21

172

Participants Needed

4

Research Sites

78 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to compare the effectiveness and remaining refractive error of two types of phakic toric intraocular lenses in patients with moderate to high myopia and astigmatism. The study also evaluates and compares the safety of the EYECRYLTM Phakic Toric lens versus the Visian4 Toric Implantable Contact Lens in this patient group. Phakic intraocular lenses are clear lenses surgically placed in the eye without removing the natural lens, helping to improve uncorrected vision by focusing light correctly on the retina. Participants will be randomly assigned to receive one of two treatments: the Eyecryl Phakic Toric intraocular lens or the Visian4 Toric Implantable Contact Lens. Both lenses are designed to correct myopia and astigmatism and are implanted either in the anterior or posterior chamber of the eye. The study involves surgical placement of these lenses to assess their performance and safety over time. During the study, participants will attend all scheduled follow-up visits to monitor visual outcomes and safety. Researchers will measure the mean residual refractive error six months after lens implantation as the primary outcome. Safety assessments and other evaluations will also be conducted to track the lenses' effects. The study started in October 2021 and is expected to continue until February 2027, with ongoing monitoring of participants' vision and eye health.

CONDITIONS

Brief Title

A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses

Who Can Participate

Age: 21Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients 21 years old or older
  • Calculated IOL Power is within the range of the investigational IOLs
  • Corneal Cylindrical error within the range defined in the clinical investigation plan
  • Monocular uncorrected visual acuity (UCVA) 0.5 LogMAR or worse
  • Stable refraction (±0.5D; ±1.0D for higher refractive errors) for at least 12 months prior to surgery
  • Contact lens wearers must show stable refraction (±0.5D) on two consecutive exams with at least 7 days apart and no contact lens use for at least 2 weeks or 3 days before first refraction
  • Expected residual postoperative cylindrical refractive error of ≥1D must have experienced best spectacle vision with anticipated correction
  • Expected dilated pupil size large enough to visualize the axis marking
  • Willingness to attend all follow-up appointments
  • Signed and provided informed consent form
Not Eligible

You will not qualify if you...

  • Acute or chronic disease increasing operative risk or confounding outcomes
  • Use of systemic medication that may affect study results or increase risk
  • Ocular conditions predisposing to future complications
  • Previous intraocular or corneal surgery
  • Endothelial cell density less than 2000 cells/mm² at enrollment
  • Pregnant, planning pregnancy, or lactating during the study
  • Conditions causing hormonal fluctuations
  • Anterior chamber depth less than 2.8 mm measured from the endothelium
  • Participation in another drug or device study
  • Presence of any cataract
  • Coefficient of variation of endothelial cell area greater than 0.45
  • Percent hexagonality of endothelial cell shape less than or equal to 45%
  • Monocular subjects
  • Vulnerable subjects as defined in section 12.3.10

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - 1 day

Participants undergo surgical implantation of a phakic toric intraocular lens to improve uncorrected visual acuity by correcting myopia and astigmatism.

1 surgical visit

Post-operative Follow-up

Duration - 6 months

Participants are monitored after surgery to assess outcomes and ensure proper recovery.

Approximately 6 post-operative visits

Trial Site Locations

Total: 4 locations

1

Precise Vision Augentagesklinik Greven

Münster, North Rhine-Westphalia, Germany, 48268

Actively Recruiting

2

Precise Vision Augentagesklinik Rheine

Rheine, North Rhine-Westphalia, Germany, 48429

Actively Recruiting

3

Precise Vision Augentagesklinik Rheine

Steinfurt, North Rhine-Westphalia, Germany, 48429

Actively Recruiting

4

Netradhama Superspeciality Eye Hospital

Bangalore, Karnataka, India, 560 082

Actively Recruiting

Loading map...

Research Team

B

BHARGAV D JOSHI, M.Sc.

H

Hatice B Deveci Summer, B.Sc

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here